*仅供医学专业人士阅读参考
*以下内容仅供医疗卫生专业人士浏览。
参考文献：
[1]Wangxia Lv, et al. A multi-cohort real-world study of treatment for metastatic colorectal cancer (mCRC): Overall efficacy analysis and subgroup analysis of previous bevacizumab use or not. JCO 43, e15530-e15530(2025).
[2]Fukuoka S, et al. J Clin Oncol. 2020;38(18):2053-2061.
[3]JAMA 2018;319(24):1-11.
[4]Lancet 2023;402(10395):41-53.
[5]Qin SK, Li J, Xu RH, et al. To Evaluate the Efficacy of Fruquintinib versus Regorafenib and Trifluridine/Tipiracil in Treating Advanced Metastatic Colorectal Cancer: A Match-adjusted Indirect Comparison. 2025 ASCO. #Abstract.
[6]Xu L, Qu JL, Cheng Y, et al. Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer. 2025 ASCO. #Abstract.
[7]Jia R, Wang ZK, Han QL, et al. Preliminary results of fruquintinib in combination with FOLFIRl as second-linetreatment for RAS-mutant metastatic colorectal cancer:a prospective,single-centerphase 2 study. 2025 ASCO. #Abstract.
[8]2024 JSCO. Abstract No.3000184.
[9]JCO 41, 152-152(2023).
[10]2024 ASCO Abstract TPS3643.
NP-AYT-25N485-Valid Until-2027-June
本资料由和黄医药提供支持
本资料旨在促进医药信息的沟通和交流，而非广告宣传。本资料内容不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。若您想了解更多有关疾病知识的信息，请咨询医疗卫生专业人士。
热门跟贴